Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer.

Side effects (toxicity) information will also be collected.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Erlotinib Hydrochloride; Fluorouracil; Paclitaxel

Criteria

Inclusion Criteria:

• Clinically confirmed esophageal or gastroesophageal junction cancer stage I, II or III

• No prior treatment for esophageal cancer

• Must be surgical candidate based on stage and location of disease

• Measurable or evaluable disease

• Able to be up and perform self care

• Adequate liver, renal function and bone marrow function

• Patients will have to have a central venous access device placed

• Able to give written informed consent.

• Age 18 or older

Exclusion Criteria:

• Stage IV disease

• Prior cancer treatment for advanced cancer in the last 5 years

• Pregnant or lactating women

• History of stroke, transient ischemic attacks, or acute MI within the past 6 months or any other serious cardiovascular disease

• History of neurological disease

• Recent history of blood in the sputum or vomitus

• Non-healing wounds, ulcer or long bone fractures

• History of bleeding problems or coagulation problems

• History of abdominal fistula, gi perforation or intrabdominal abscess within 6 months

• History of uncontrolled hypertension

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.